Print this Article
RSSBusiness Wire
eFoodSafety.com, Inc. (OTCBB:EFSF) has signed a distribution agreement with NutraLab, Inc. to conduct a direct response marketing campaign to sell Trimmendous, a weight loss regimen that helps improve metabolism and increase energy levels. It was announced today by Patricia Ross-Gruden, President and CEO. According to the National Institutes of Health, Americans spent $33 billion annually on weight-loss products and services and products such as Trimmendous can help to cut that cost.
Trimmendous is a two-step formula that enables metabolic processes to become more efficient during the day, and enhances a deep uninterrupted sleep at night. Very few products address the concept of both increasing energy, metabolism and appetite suppression during the day, and then increasing relaxation, reducing stress and cravings, and improving sleep at night. The AM formula helps metabolism and appetite control at the same time, without questionable stimulants like ephedra or bitter orange. The PM formula aids the body's natural sleep patterns without causing grogginess or dependence. It does not contain melatonin, 5HTP, Kava, Valerian, Chamomile or Skullcap.
"Our Trimmendous product offers dieters a whole-body solution for long-term weight loss management without the harmful side effects of competitors' 'slim-quick' type products," stated Patricia Ross-Gruden. "We are proud to take an initiative to bring to market a quality formula that can better the population on these fronts."
Other weight-loss products or "energy diet supplements" cannot be taken past 5 or 6 PM because they will restrict sleep, so the dieter is left to fend for themselves at night when binging tends to be more common. Competitive products with sleep components are usually very weak, and are just throw-ins for marketing purposes.
About eFoodSafety.com, Inc.
eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous, a weight loss formula emphasizing on the body's 24-hour metabolic processes.
Safe Harbor Forward-Looking Statements
Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
